​

FibroBiologics Stock (NASDAQ:FBLG)

RevenueOwnershipFinancialsChart
FibroBiologics by TradingView

Previous Close

$0.35

52W Range

$0.24 - $2.51

50D Avg

$0.37

200D Avg

$0.69

Market Cap

$16.02M

Avg Vol (3M)

$1.21M

Beta

-0.57

Div Yield

-

FBLG Company Profile

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 01, 2024

Website

FBLG Performance

FBLG Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-13.74M$-8.89M$-4.47M
Net Income$-11.16M$-16.48M$-5.12M
EBITDA$-13.74M$-15.90M$-4.37M
Basic EPS$-0.34$-0.59$-0.16
Diluted EPS$-0.34$-0.68$-0.16

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
DAREDaré Bioscience, Inc.
HOTHHoth Therapeutics, Inc.
MBRXMoleculin Biotech, Inc.
ICUSeaStar Medical Holding Corporation
ATHAAthira Pharma, Inc.
ADTXAditxt, Inc.
APLMApollomics, Inc.
LPTXLeap Therapeutics, Inc.
CTXRCitius Pharmaceuticals, Inc.
AIMDAinos, Inc.